Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Pawel, Joachim von; Schiller, Joan H.; Shepherd, Frances A.; Fields, Scott Z.; Kleisbauer, J P; Chrysson, Nick G.; Stewart, David J.; Clark, Peter; Palmer, Martin; Depierre, A; Carmichael, James; Krebs, Jacqueline B.; Ross, Graham; Lane, Stephen R.; Gralla, Richard J.

doi:10.1200/jco.1999.17.2.658

Cited by 843 publications

(563 citation statements)

References 21 publications

Supporting

Mentioning

525

Contrasting

Unclassified

Order By: Relevance

“…In addition to the randomized trial comparing oral topotecan with BSC mentioned above, 2 phase 3 trials for recurrent SCLC have been reported to date. 14,15 A trial comparing intravenous topotecan with the combination of cyclophosphamide, doxorubicin, and vincristine demonstrated comparable response rates and survival; however, intravenous topotecan yielded greater symptomatic improvement for 4 of the 8 symptoms evaluated. 14 In the other trial, comparing oral topotecan with intravenous topotecan, no survival difference was observed.…”

Section: Discussionmentioning

confidence: 99%

Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy

Kim

Goto

Yoh

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND To the authors' knowledge, the prognostic factors in recurrent small cell lung cancer (SCLC) patients treated with second‐line chemotherapy have not yet been clearly identified to date. METHODS Between July 1992 and December 2003, 232 of 515 patients who were diagnosed to have SCLC at the National Cancer Center Hospital East were administered second‐line chemotherapy for recurrent disease. The authors retrospectively analyzed the relation between clinical factors evaluated at the time of recurrence and the response to second‐line chemotherapy or survival in these patients. RESULTS The results of univariate analyses revealed that response was significantly associated with the performance status (PS) alone, whereas survival was significantly associated with the PS, disease extent, and sensitivity to first‐line chemotherapy. Multivariate analysis identified PS (P < .0001) and sensitivity to first‐line chemotherapy (P = .0024) as the independent prognostic factors for survival. When the patients were grouped according to these 2 significant prognostic factors, the survival of patients with a PS of 0 to 1 was significantly better than that of the patients with a PS of 2 to 4 both among cases that were sensitive and those that were refractory to first‐line chemotherapy. Although the survival of sensitive recurrent cases was significantly better than that of the refractory recurrent cases among the patients with a PS of 0 to 1 patients, no survival difference was observed between the sensitive and refractory recurrent cases in the patients with a PS of 2 to 4. CONCLUSIONS Both PS and sensitivity to initial chemotherapy were found to be significant prognostic factors for survival in recurrent SCLC patients treated with second‐line chemotherapy. These 2 factors should therefore be used as stratification factors in future clinical trials. Cancer 2008. © 2008 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy

Kim

Goto

Yoh

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…8 The next step was a randomized comparison of topotecan and the combination of cyclophosphamide, doxorubicin and vincristine (CAV) in patients who had relapsed more than 3 months after completion of first line therapy. 9 Topotecan proved to be as effective as CAV in terms of response, but was more effective in controlling a number of disease-related symptoms. In the next randomized trial, topotecan was tested after completion of first-line therapy in patients with extensive stage SCLC.…”

Section: First or Second Line?mentioning

confidence: 98%

Topotecan in Small Cell Lung Cancer: First or Second Line?

Campling¹

2004

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…In SCLC, topotecan has comparable response rates and survival to CAV (cyclophosphamide 1,000 mg/m 2 , doxorubicin 45 mg/m 2 , and vincristine 2 mg, D1, every 21 days) with less toxicity. 99 Oral topotecan 2.3 mg/m 2 /day for 5 days, when compared to intravenous 1.5 mg/m 2 /day for 5 days every 21 days, resulted in comparable median survival at 2 years, therefore constituting an alternative to the intravenous formulation. 100 …”

Section: Recommendationmentioning

confidence: 99%

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Moretto

Wood

Emmenegger

et al. 2013

CUAJ

View full text Add to dashboard Cite

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Abstract: Topotecan was at least as effective as CAV in the treatment of patients with recurrent SCLC and resulted in improved control of several symptoms.

Cited by 843 publications

References 21 publications

Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy

Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy

Topotecan in Small Cell Lung Cancer: First or Second Line?

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Contact Info

Product

Resources

About